Regenerative Medicine Group Expresses Concerns With REGROW Act

The Alliance for Regenerative Medicine (ARM) says it won't support a bipartisan bill that would offer a five-year conditional approval for regenerative medicine products because the bill could lead to marketing of products that have not been proven to be safe and effective. The group also takes issue with provisions of the Reliable and Effective Growth for Regenerative Health Options that Improve Wellness (REGROW) Act that would streamline approval of devices associated with cell therapies. The sponsors of the REGROW...